Evidence map›Paper›PMID 39842691›Full record

ArticleContemporary clinical trials2025

Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).

Matisyahu Shulman, Sarah Meyers-Ohki, Patricia Novo, Scott Provost, Kaitlyn Ohrtman, Paul Van Veldhuisen, Neal Oden, Michael Otterstatter, Genie L Bailey, David Liu and 3 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04464980 (NIDA-CTN-0100), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04464980 phase2active not recruitingnot on this map

NIDA-CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

TypeinterventionalSponsorNYU Langone HealthRan2021 to 2027Enrolled1,516ConditionsOpioid Use Disorder (OUD)ArmsSL-BUP, XR-BUP, XR-NTX, MM, MMR
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Matisyahu ShulmanNew York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, USA; Columbia University Irving Medical Center, 630 West 168(th) St., New York, NY 10032, USA. Electronic address: matisyahu.shulman@nyspi.columbia.edu.
Sarah Meyers-OhkiNew York University Grossman School of Medicine, 550 1(st) Ave., New York, NY 10016, USA. Electronic address: sarah.meyers-ohki@nyulangone.org.
Patricia NovoNew York University Grossman School of Medicine, 550 1(st) Ave., New York, NY 10016, USA. Electronic address: patricia.novo@nyulangone.org.
Scott ProvostMcLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA 02478, USA. Electronic address: sprovost@mclean.harvard.edu.
Kaitlyn OhrtmanNew York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, USA; Columbia University Irving Medical Center, 630 West 168(th) St., New York, NY 10032, USA. Electronic address: kaitlyn.ohrtman@nyspi.columbia.edu.
Paul Van VeldhuisenThe Emmes Company, LLC, 401 N Washington St., #700, Rockville, MD 20850, USA. Electronic address: pvanveldhuisen@emmes.com.
Neal OdenThe Emmes Company, LLC, 401 N Washington St., #700, Rockville, MD 20850, USA. Electronic address: noden@emmes.com.
Michael OtterstatterThe Emmes Company, LLC, 401 N Washington St., #700, Rockville, MD 20850, USA. Electronic address: motterstatter@emmes.com.
Genie L BaileyWarren Alpert School of Medicine of Brown University / Stanley Street Treatment and Resources, Inc., 222 Richmond St., Providence, RI 02903, USA. Electronic address: genie_bailey@brown.edu.
David LiuNational Institute on Drug Abuse, 11601 Landsdown St., North Bethesda, MD 20852, USA. Electronic address: dliu@nida.nih.gov.
John RotrosenNew York University Grossman School of Medicine, 550 1(st) Ave., New York, NY 10016, USA. Electronic address: john.rotrosen@nyulangone.org.
Roger D WeissMcLean Hospital/Harvard Medical School, 115 Mill St., Belmont, MA 02478, USA. Electronic address: rweiss@mclean.harvard.edu.
Edward V NunesNew York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, USA; Columbia University Irving Medical Center, 630 West 168(th) St., New York, NY 10032, USA. Electronic address: edward.nunes@nyspi.columbia.edu.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA015831
6 · The paper itself

Abstract

INTRODUCTION AND

backgroundThe three medications approved to address OUD are effective in decreasing opioid use and morbidity and mortality; however, their utility is limited by high rates of dropout from treatment. The CTN-0100 trial will develop an evidence base for strategies to improve retention on buprenorphine and extended-release naltrexone. RESEARCH DESIGN AND

methodsThe National Drug Abuse Treatment Clinical Trials Network (CTN) study CTN-0100, "Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy" (RDD), is a multicenter, randomized, non-blinded trial enrolling more than a thousand patients from 18 community-based substance use disorder treatment programs. Participants are adult volunteers seeking to initiate medication treatment for OUD (MOUD). Individuals choose between buprenorphine or extended-release injectable naltrexone. The trial randomizes participants choosing buprenorphine, in a 3 × 2 factorial design, to a medication condition (standard-dose sublingual buprenorphine, high-dose sublingual buprenorphine, or extended-release injectable buprenorphine) and to a behavioral condition (Medical Management or Medical Management plus a digital therapeutic (smartphone) app). Individuals choosing extended-release naltrexone are randomized only to a behavioral condition. Participants receive study medication for 74 weeks and are then followed for a further 24 weeks. The primary outcome is successful retention on MOUD at 26 weeks (six months), with 50- and 74-week retention among the secondary outcomes. DISCUSSION/

conclusionDropout from treatment is a major barrier to the effectiveness of MOUD. The CTN-0100 study will determine whether strategies such as high dose sublingual or extended-release buprenorphine, or an app-based behavioral intervention improve retention on MOUD. CLINICALTRIALS: gov Identifier: NCT04464980.

Indexed as

BuprenorphineNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersAdministration, SublingualAdultDelayed-Action PreparationsFemaleHumansMaleMulticenter Studies as TopicPatient DropoutsRandomized Controlled Trials as TopicBuprenorphineDelayed-Action PreparationsNaltrexoneNarcotic AntagonistsAutomated psychosocial interventionBuprenorphineNaltrexoneOpioidsOpioid use disorderTreatment

Identifiers

PMID39842691
PMCPMC11867840

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.